• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ESSA Pharma Inc. (Amendment)

    2/14/23 2:50:20 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EPIX alert in real time by email
    SC 13G/A 1 essapharma13ga.htm SC 13G/A

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 7)*

    Essa Pharma Inc.

    (Name of Issuer – as specified in its charter)

    Common Shares

    (Title of Class of Securities)

    29668H708

    (CUSIP Number)

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    þ        Rule 13d-1(b)

    ¨        Rule 13d-1(c)

    ¨        Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

     

    1

    NAME OF REPORTING PERSON

    Eventide Asset Management, LLC

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    ¨ (a)

    ¨ (b)

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

    0

     

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

     

    12

    TYPE OF REPORTING PERSON

    IA

           

     

     
     

     

    1

    NAME OF REPORTING PERSON

    Finny Kuruvilla, M.D. Ph. D.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    ¨ (a)

    ¨ (b)

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

    0

     

    6

    SHARED VOTING POWER

    0

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

     

    12

    TYPE OF REPORTING PERSON

    IN;HC

           

     

     
     

     

    1

    NAME OF REPORTING PERSON

    Robin C. John

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    ¨ (a)

    ¨ (b)

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

    0

     

    6

    SHARED VOTING POWER

    0

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

     

    12

    TYPE OF REPORTING PERSON

    IN;HC

           

     

     
     

    Item 1. (a) Name of Issuer:

    Essa Pharma Inc. (the “Issuer”)

    (b) Address of Issuer’s Principal Executive Offices:

    Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5

    Item 2. (a) Name of Persons Filing:

    (i) Eventide Asset Management, LLC (“Eventide”)

    (ii) Finny Kuruvilla, M.D., Ph.D. (“Kuruvilla”)

    (iii) Robin C. John (“John”)

    (b). Address of Principal Business Office or, if none, Residence:

    Eventide, Kuruvilla and John:

    One International Place, Suite 4210

    Boston, Massachusetts 02110

    (c). Citizenship or Place of Organization:

    Eventide: Delaware

    Kuruvilla: United States

    John: United States

    (d). Title of Class of Securities:

    Common Shares

     

    (e). CUSIP Number:

    29668H708

    Item 3. If this statement is filed pursuant to sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

    (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

    (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

    (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

    (e) [x] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E);

    (f) [ ] An employee benefit plan or endowment fund in accordance with section 240.13d- 1(b)(1)(ii)(F);

    (g) [x] A parent holding company or control person in accordance with section 240.13d- 1(b)(1)(ii)(G);

    (h) [ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance

    Act (12 U.S.C. 1813);

    (i) [ ] A church plan that is excluded from the definition of an investment company under

     
     

            section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j) [ ] A non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J);

    (k) [ ] A group, in accordance with section 240.13d-1(b)(1) (ii)(K).

    If filing as a non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

    Item 4. Ownership:

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

    (a). Amount beneficially owned:   
       (i) Eventide:  0
       (ii) Kuruvilla:  0
       (iii) John:  0
    (b). Percent of class:   
          0.0%
       (ii) Kuruvilla:  0.0%
       (iii) John:  0.0%
    (c). Number of shares as to which the person has:   
    (i)        Sole power to vote or to direct the vote:   
       (1) Eventide:  0
       (2) Kuruvilla:  0
       (3) John:  0
    (ii)        Shared power to vote or to direct the vote:   
        
       (1) Eventide:  0
       (2) Kuruvilla:  0
       (3) John:  0
    (iii) Sole power to dispose or to direct the disposition of:
       (1) Eventide:  0
       (2) Kuruvilla:  0
       (3) John:  0
    (iv) Shared power to dispose or to direct the disposition of:
       (1) Eventide:  0
       (2) Kuruvilla:  0
       (3) John:  0
     
     

    Item 5. Ownership of Five Percent or Less of a Class:

    This statement is being filed to report the fact that as of the date hereof Eventide Asset Management, LLC has ceased to be the beneficial owner of more than five percent of the Issuer’s outstanding Common Shares.

    Item 6.Ownership of More Than Five Percent on Behalf of Another Person:

    Not Applicable

    Item 7.Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company:

    Not Applicable

    Item 8. Identification and Classification of Members of the Group:

    Not Applicable

    Item 9. Notice of Dissolution of Group:

    Not Applicable

    Item 10.Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.

     
     

    SIGNATURES

     

    The undersigned certify, after reasonable inquiry and to the best knowledge and belief of the undersigned, that the information set forth in this Statement is true, complete and correct. The undersigned agree to the filing of this single Statement on Schedule 13G.

     

    Eventide Asset Management, LLC

    Date: February 10, 2023                                    By: /s/ Jennifer Reiche

    Name: Jennifer Reiche

    Title: Chief Compliance Officer

     

    Finny Kuruvilla, M.D., Ph. D.

    Date: February 10, 2023                                     By: /s/ Finny Kuruvilla, M.D., Ph. D.

    Name: Finny Kuruvilla, M.D., Ph. D.

    Robin C. John

    Date: February 10, 2023                                     By: /s/ Robin C. John

    Name: Robin C. John

     
     

     

    EXHIBIT 1

    WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in writing that such Statement or amendments thereto is filed on behalf of each of them;

    NOW, THEREFORE, the parties hereto agree as follows:

    Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph. D. and Robin C. John do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file a Statement on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Statement on Schedule 13G shall be filed on behalf of each of them.

    Eventide Asset Management, LLC

    Date: February 10, 2023                                    By: /s/ Jennifer Reiche

    Name: Jennifer Reiche

    Title: Chief Compliance Officer

     

    Finny Kuruvilla, M.D., Ph. D.

    Date: February 10, 2023                                     By: /s/ Finny Kuruvilla, M.D., Ph. D.

    Name: Finny Kuruvilla, M.D., Ph. D.

    Robin C. John

    Date: February 10, 2023                                     By: /s/ Robin C. John

    Name: Robin C. John

    Get the next $EPIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EPIX

    DatePrice TargetRatingAnalyst
    11/4/2024Buy → Hold
    Jefferies
    11/4/2024Outperform → Perform
    Oppenheimer
    11/4/2024$15.00 → $2.00Overweight → Neutral
    Piper Sandler
    6/26/2023$17.00Outperform
    Oppenheimer
    8/17/2021$36.00 → $22.00Outperform
    Oppenheimer
    More analyst ratings

    $EPIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ESSA Pharma downgraded by Jefferies

    Jefferies downgraded ESSA Pharma from Buy to Hold

    11/4/24 8:34:37 AM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ESSA Pharma downgraded by Oppenheimer

    Oppenheimer downgraded ESSA Pharma from Outperform to Perform

    11/4/24 7:26:24 AM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ESSA Pharma downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded ESSA Pharma from Overweight to Neutral and set a new price target of $2.00 from $15.00 previously

    11/4/24 7:26:03 AM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EPIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ESSA Announces Completion of Arrangement with XenoTherapeutics

    SOUTH SAN FRANCISCO, Calif., USA and VANCOUVER, BC, Canada, Oct. 9, 2025 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ:EPIX) ("ESSA" or the "Company") today announced the completion of XenoTherapeutics' ("Xeno") previously announced acquisition of ESSA (the "Acquisition"). Xeno Acquisition Corp., a wholly owned subsidiary of Xeno, has acquired all of the outstanding common shares of ESSA (the "Common Shares") for approximately US$0.1242 per Common Share, plus one contingent value right ("CVR") per Common Share, which CVR represents the right to receive up to approximately US$0.14 per CVR and payable within specified periods following the close of the Acquisition. The potential CVR payment of US$0

    10/9/25 7:00:00 AM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ESSA Securityholders Approve Acquisition by XenoTherapeutics

    SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, Oct. 6, 2025 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ:EPIX) ("ESSA" or the "Company") is pleased to announce that its Securityholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the "Common Shares" and the holders of such Common Shares, the "Shareholders") by XenoTherapeutics Inc. ("Xeno"), a non-profit biotechnology company, by way of a statutory plan of arrangement (the "Transaction" or the "Arrangement") at the special meeting of Securityholders held today (the "Meeting"). The special resolution approving the Arrangement was approved by: (i) 99.83% of the votes cast by S

    10/6/25 5:14:00 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim Order

    SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 30, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX) today announced that, in connection with its previously announced Business Combination Agreement with XenoTherapeutics Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding common shares of ESSA (the "Transaction"), ESSA received an amended Interim Order from the Supreme Court of British Columbia (the "Court") on September 25, 2025. The amended Interim Order approves the previously announced date for ESSA's special meeting of the holders of common shares of the Company, optionholders and warrantho

    9/30/25 4:30:00 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EPIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Parkinson David Ross bought $21,213 worth of shares (9,223 units at $2.30), increasing direct ownership by 16% to 65,675 units (SEC Form 4)

    4 - ESSA Pharma Inc. (0001633932) (Issuer)

    12/18/23 9:57:03 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Berger Franklin M bought $133,274 worth of shares (23,259 units at $5.73), increasing direct ownership by 3% to 784,404 units (SEC Form 4)

    4 - ESSA Pharma Inc. (0001633932) (Issuer)

    11/22/23 6:22:47 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Berger Franklin M bought $419,661 worth of shares (76,471 units at $5.49), increasing direct ownership by 11% to 760,875 units (SEC Form 4)

    4 - ESSA Pharma Inc. (0001633932) (Issuer)

    11/16/23 5:45:43 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EPIX
    SEC Filings

    View All

    SEC Form EFFECT filed by ESSA Pharma Inc.

    EFFECT - ESSA Pharma Inc. (0001633932) (Filer)

    11/17/25 12:15:16 AM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by ESSA Pharma Inc.

    SCHEDULE 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

    11/14/25 4:17:03 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by ESSA Pharma Inc.

    SCHEDULE 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

    11/14/25 4:15:19 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EPIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Parkinson David Ross returned 65,675 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - ESSA Pharma Inc. (0001633932) (Issuer)

    10/15/25 12:04:51 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Wood David S. returned 33,343 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - ESSA Pharma Inc. (0001633932) (Issuer)

    10/15/25 12:03:22 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Berger Franklin M returned 784,404 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - ESSA Pharma Inc. (0001633932) (Issuer)

    10/15/25 12:01:44 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EPIX
    Leadership Updates

    Live Leadership Updates

    View All

    ESSA Securityholders Approve Acquisition by XenoTherapeutics

    SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, Oct. 6, 2025 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ:EPIX) ("ESSA" or the "Company") is pleased to announce that its Securityholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the "Common Shares" and the holders of such Common Shares, the "Shareholders") by XenoTherapeutics Inc. ("Xeno"), a non-profit biotechnology company, by way of a statutory plan of arrangement (the "Transaction" or the "Arrangement") at the special meeting of Securityholders held today (the "Meeting"). The special resolution approving the Arrangement was approved by: (i) 99.83% of the votes cast by S

    10/6/25 5:14:00 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

    SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, March 6, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on March 5, 2025 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at seven and re-elected to the board of directors, by ordinary resolution passed by ballot

    3/6/25 7:00:00 AM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

    SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024  /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin M. Berg

    3/7/24 8:13:00 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EPIX
    Financials

    Live finance-specific insights

    View All

    Essa Pharma Inc. Clarifies Nasdaq Due Bill Trading for Previously Announced Cash Distribution

    SOUTH SAN FRANCISCO, Calif and VANCOUVER, BC, Aug. 25, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX) announced on August 14, 2025 that, in connection with the Company's previously announced return of capital distribution in the aggregate amount of US$80,000,000 (the "Distribution") to the holders of common shares of the Company ("Common Shares" and the holders of such Common Shares, the "Shareholders") as part of the discontinuance and winding-up of the business of the Company pursuant to the Company's previously announced transaction with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire all of the issued and

    8/25/25 3:54:00 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Essa Pharma Inc. Announces Ex-Dividend Date and Nasdaq Due Bill Trading for Previously Announced Cash Distribution

    SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX) today announced that, in connection with the Company's recently announced return of capital distribution in the aggregate amount of US$80,000,000 (the "Distribution") to the holders of common shares of the Company ("Common Shares" and the holders of such Common Shares, the "Shareholders") as part of the discontinuance and winding-up of the business of the Company pursuant to the Company's previously announced transaction with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding Co

    8/14/25 4:30:00 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction

    SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC and BOSTON and EMERYVILLE, Calif., July 14, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX) today announced that it has entered into a definitive agreement (the "Business Combination Agreement") with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire (the "Transaction") all of the issued and outstanding common shares of ESSA (the "Common Shares"). XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), the biotechnology royalty aggregator, is acting as the structuring agent and will provide financing to Xeno for this Transaction. Under the terms of the Business Combi

    7/14/25 8:00:00 AM ET
    $EPIX
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EPIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ESSA Pharma Inc.

    SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

    11/14/24 7:32:27 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ESSA Pharma Inc.

    SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

    11/14/24 4:04:37 PM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ESSA Pharma Inc.

    SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

    11/14/24 6:56:05 AM ET
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care